Immune Depletion With Cellular Mobilization Imparts Immunoregulation and Reverses Autoimmune Diabetes in Nonobese Diabetic Mice
Open Access
- 23 July 2009
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 58 (10), 2277-2284
- https://doi.org/10.2337/db09-0557
Abstract
OBJECTIVE: The autoimmune destruction of β-cells in type 1 diabetes results in a loss of insulin production and glucose homeostasis. As such, an immense interest exists for the development of therapies capable of attenuating this destructive process through restoration of proper immune recognition. Therefore, we investigated the ability of the immune-depleting agent antithymocyte globulin (ATG), as well as the mobilization agent granulocyte colony–stimulating factor (GCSF), to reverse overt hyperglycemia in the nonobese diabetic (NOD) mouse model of type 1 diabetes.RESEARCH DESIGN AND METHODS: Effects of each therapy were tested in pre-diabetic and diabetic female NOD mice using measurements of glycemia, regulatory T-cell (CD4+CD25+Foxp3+) frequency, insulitis, and/or β-cell area.RESULTS: Here, we show that combination therapy of murine ATG and GCSF was remarkably effective at reversing new-onset diabetes in NOD mice and more efficacious than either agent alone. This combination also afforded durable reversal from disease (>180 days postonset) in animals having pronounced hyperglycemia (i.e., up to 500 mg/dl). Additionally, glucose control improved over time in mice subject to remission from type 1 diabetes. Mechanistically, this combination therapy resulted in both immunological (increases in CD4-to-CD8 ratios and splenic regulatory T-cell frequencies) and physiological (increase in the pancreatic β-cell area, attenuation of pancreatic inflammation) benefits.CONCLUSIONS: In addition to lending further credence to the notion that combination therapies can enhance efficacy in addressing autoimmune disease, these studies also support the concept for utilizing agents designed for other clinical applications as a means to expedite efforts involving therapeutic translation.Keywords
This publication has 45 references indexed in Scilit:
- The defect in T-cell regulation in NOD mice is an effect on the T-cell effectorsProceedings of the National Academy of Sciences, 2008
- Poor in vitro induction of FOXP3 and ICOS in type 1 cytokine environment activated T‐cells from children with type 1 diabetesDiabetes/Metabolism Research and Reviews, 2008
- Relationship between β‐cell mass and diabetes onsetDiabetes, Obesity and Metabolism, 2008
- Human alpha 1-antitrypsin therapy induces fatal anaphylaxis in non-obese diabetic miceClinical and Experimental Immunology, 2008
- Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCTBone Marrow Transplantation, 2008
- A Microsphere-Based Vaccine Prevents and Reverses New-Onset Autoimmune DiabetesDiabetes, 2008
- Granulocyte Colony-Stimulating Factor for the Induction of T-Cell ToleranceTransplantation, 2007
- Elimination of insulitis and augmentation of islet β cell regeneration via induction of chimerism in overtly diabetic NOD miceProceedings of the National Academy of Sciences of the United States of America, 2007
- G-CSF treatment prevents cyclophosphamide acceleration of autoimmune diabetes in the NOD mouseJournal of Autoimmunity, 2005
- Polyclonal Anti-T-Cell Therapy for Type 1 Diabetes Mellitus of Recent OnsetThe Review of Diabetic Studies, 2004